Ken Griffin Absci Corp Call Options Transaction History

Citadel Advisors LLC

8 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2024 Aug 14, 2024	SELL	$2.92 - $6.58 $21,608 - $48,692	-7,400 Reduced 26.43%	20,600 $63,000
Q1 2024 May 15, 2024	SELL	$3.41 - $5.74 $124,806 - $210,084	-36,600 Reduced 56.66%	28,000 $159,000
Q4 2023 Feb 14, 2024	BUY	$1.15 - $4.79 $68,080 - $283,568	59,200 Added 1096.3%	64,600 $271,000
Q3 2023 Nov 14, 2023	SELL	$1.28 - $2.41 $18,304 - $34,463	-14,300 Reduced 72.59%	5,400 $7,000
Q2 2023 Aug 14, 2023	SELL	$1.17 - $2.03 $5,733 - $9,946	-4,900 Reduced 19.92%	19,700 $29,000
Q1 2023 May 15, 2023	BUY	$1.58 - $3.41 $28,598 - $61,721	18,100 Added 278.46%	24,600 $43,000
Q4 2022 Feb 14, 2023	SELL	$2.0 - $3.58 $43,800 - $78,402	-21,900 Reduced 77.11%	6,500 $13,000
Q3 2022 Nov 14, 2022	BUY	$2.95 - $4.83 $83,780 - $137,172	28,400 New	28,400 $89,000

115

55.3M

190K

114K

Ticker ABSI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 92,843,504
Market Cap $383M
Description
Absci Corporation, a drug and target discovery company, provides biologic drug candidates and production cell lines using integrated drug creation platform for partners in the United States. Its integrated drug creation platform enables the creation of biologics by unifying the drug discovery and cell line development processes into one process....

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.